Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Biotech/Pharma News
-
By Baltazar Gomez — We previously reported on the passage by the U.S. Senate Committee on Health, Education, Labor & pensions of bill S.1695, entitled "The Biologics Price Competition and Innovation Act of 2007." The bill’s sponsors stated that the bill reflects a balanced approach that enables patients to have safe and effective…
-
By Kevin E. Noonan — Ophthalmologists and Genentech have forged a compromise over the availability of Genentech’s anticancer drug, Avastin®, for use in treating neovascular or "wet" age-related macular degeneration (AMD). The controversy arose when Genentech decided to ban compounding pharmacies from reformulating Avastin® (bevacizumab, a monoclonal antibody) to be used for treating…
-
By Kevin E. Noonan — Keith Olbermann, former ESPN co-anchor of SportsCenter and for the past few years the host of MSNBC’s Countdown, has noted the correlation between bad political news for the Bush administration and heightening of terror threat warnings (see "The Nexus of Politics and Terror," Countdown, 10/12/2005). While not in…
-
By Kevin E. Noonan — There is something about biotechnology that brings out the Cassandras (which is being kind; "Chicken Little" is a more accurate characterization) in people who oppose it. Whether motivated by a renewed "vitalism" (see "Science Fiction in The New York Times") or some kind of green (or Green) impulse,…
-
By Kevin E. Noonan — For the past several months, Genentech has been assailed by ophthalmologists and patients over its decision to ban compounding pharmacies from reformulating its anticancer drug Avastin® (bevacizumab, a monoclonal antibody) to be used for treating neovascular or "wet" age-related macular degeneration (AMD), a condition that if untreated leads…
-
By Kevin E. Noonan — It is always surprising to non-scientists when they discover how little we know about the answers to some fundamental questions. Everyone knows, of course, the paradox that "we can land a man on the moon, but we can’t prevent the common cold." More esoterically, Dr. J.R. Powell at…
-
By Kevin E. Noonan — Responding to outrage, protest, and threats of political and legal action, or perhaps just belatedly recognizing that it was in the middle of a public relations nightmare, Genentech last week announced that it would delay until the end of the year implementation of its decision to "no longer…
-
By Kevin E. Noonan — Claude Barfield and John E. Calfee of the American Enterprise Institute opined on the Op-Ed page of The Wall Street Journal last Monday, discussing the wisdom (or lack of it) in patent "reform" bills pending in Congress. While generally consistent with an informed appreciation of the benefits of…
-
By Kevin E. Noonan — The Subcommittee on Court, the Internet and Intellectual Property of the House of Representative’s Judiciary Committee has scheduled a hearing entitled "Stifling or Stimulating – The Role of Gene Patents in Research and Genetic Testing" for Tuesday, October 30, 2007. While not stating so on the hearing notice,…
-
By Kevin E. Noonan — Earlier this year, Patent Docs had several posts relating to the use of an anticancer drug, Avastin® (bevacizumab, a monoclonal antibody), for treating neovascular or "wet" age-related macular degeneration (AMD), a condition that if untreated leads inexorably to blindness (see links below). This is an off-label use; another…
Patent Docs 